Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs

被引：7

作者：

Swe, Thein ^{[1
]}

Kim, Kevin B. ^{[1
]}

机构：

[1] Calif Pacific Med Ctr Res Inst, 2333 Buchanan St, San Francisco, CA 94115 USA

来源：

CLINICAL & EXPERIMENTAL METASTASIS | 2018年 / 35卷 / 5-6期

关键词：

Melanoma; Targeted therapy; Checkpoint inhibitor; BRAF mutation; PD-1; CTLA-4; RECOMBINANT INTERLEUKIN-2 THERAPY; INVESTIGATOR-CHOICE CHEMOTHERAPY; DABRAFENIB PLUS TRAMETINIB; COOPERATIVE-ONCOLOGY-GROUP; HERPES-SIMPLEX-VIRUS; BRAF-MUTANT MELANOMA; STAGE-III MELANOMA; METASTATIC MELANOMA; OPEN-LABEL; PHASE-II;

D O I：

10.1007/s10585-018-9913-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant melanoma is generally chemo- and radio-resistant, and patients with advanced melanoma have a poor prognosis. However, with our increased understanding of the checkpoint immune molecules and genetic alterations of melanoma cells, more effective immunotherapy, such as anti CTLA4 antibody and anti PD-1 antibodies, and targeted drug therapy, such as BRAF inhibitors and MEK inhibitors, have been developed, resulting in improved overall survival and quality of life of patients with advanced melanoma. In addition, emerging technologies to develop prognostic and predictive biomarkers for response to systemic therapy could help clinicians make more accurate assessments of the disease and formulate more effective treatment plans. In this review, current standard systemic therapy options and recently developed novel drugs for advanced melanoma are discussed.

引用

页码：503 / 520

页数：18

共 94 条

[11] Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression [J].

Chang, Gregory A. ;

Taclepalli, Jyothirmayee S. ;

Shao, Yongzhao ;

Zhang, Yilong ;

Weiss, Sarah ;

Robinson, Eric ;

Spittle, Cindy ;

Furtado, Manohar ;

Shelton, Dawne N. ;

Karlin-Neumann, George ;

Pavlick, Anna ;

Osman, Iman ;

Polsky, David .

MOLECULAR ONCOLOGY, 2016, 10 (01) :157-165

[12] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[13] Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma [J].

Chapman, PB ;

Einhorn, LH ;

Meyers, ML ;

Saxman, S ;

Destro, AN ;

Panageas, KS ;

Begg, CB ;

Agarwala, SS ;

Schuchter, LM ;

Ernstoff, MS ;

Houghton, AN ;

Kirkwood, JM .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2745-2751

[14] Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma [J].

Cooper, Zachary A. ;

Reuben, Alexandre ;

Amaria, Rodabe N. ;

Wargo, Jennifer A. .

ONCOIMMUNOLOGY, 2014, 3 (09)

[15] PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J].

Curran, Michael A. ;

Montalvo, Welby ;

Yagita, Hideo ;

Allison, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :4275-4280

[16] Somatic activation of KIT in distinct subtypes of melanoma [J].

Curtin, John A. ;

Busam, Klaus ;

Pinkel, Daniel ;

Bastian, Boris C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4340-4346

[17] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[18] Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial [J].

Davies, Michael A. ;

Saiag, Philippe ;

Robert, Caroline ;

Grob, Jean-Jacques ;

Flaherty, Keith T. ;

Arance, Ana ;

Chiarion-Sileni, Vanna ;

Thomas, Luc ;

Lesimple, Thierry ;

Mortier, Laurent ;

Moschos, Stergios J. ;

Hogg, David ;

Marquez-Rodas, Ivan ;

Del Vecchio, Michele ;

Lebbe, Celeste ;

Meyer, Nicolas ;

Zhang, Ying ;

Huang, Yingjie ;

Mookerjee, Bijoyesh ;

Long, Georgina V. .

LANCET ONCOLOGY, 2017, 18 (07) :863-873

[19] Prognostic Factors for Survival in Melanoma Patients With Brain Metastases [J].

Davies, Michael A. ;

Liu, Ping ;

McIntyre, Susan ;

Kim, Kevin B. ;

Papadopoulos, Nicholas ;

Hwu, Wen-Jen ;

Hwu, Patrick ;

Bedikian, Agop .

CANCER, 2011, 117 (08) :1687-1696

[20] Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma [J].

Devitt, Bianca ;

Liu, Wendy ;

Salemi, Renato ;

Wolfe, Rory ;

Kelly, John ;

Tzen, Chin-Yuan ;

Dobrovic, Alexander ;

McArthur, Grant .

PIGMENT CELL & MELANOMA RESEARCH, 2011, 24 (04) :666-672

← 1 2 3 4 5 6 7 8 9 10 →